樂普生物-B(02157.HK)公開發售獲超額認購5.65倍 發售價每股7.13港元
格隆匯2月22日丨樂普生物-B(02157.HK)發佈公吿，公司全球發售1.27億股股份，其中香港發售股份1268.8萬股，國際發售股份1.14億股，另有15%超額配股權；發售價釐定為每股發售股份7.13港元，每手買賣單位1000股；中金公司及摩根士丹利為聯席保薦人；預期股份將於2022年2月23日於聯交所主板掛牌上市。
香港發售股份獲小幅超額認購，已收到合共6141份有效申請，認購合共7174.6萬股香港發售股份，為香港發售股份的約5.65倍。國際發售項下初步提呈發售的發售股份獲小幅超額認購，為國際發售項下初步可供認購的發售股份總數的約1.53倍。按照發售價每股7.13港元並根據基石投資協議，基石投資者認購的發售股份數目已經確定。維梧資本及King Star已分別認購3278.9萬股及2185.9萬股，共計5464.8萬股發售股份。
按照發售價每股7.13港元，並假設超額配股權未獲行使，全球發售的所得款項淨額估計約為8.042億港元。公司擬將所得款項淨額的68.5%為核心產品撥資；所得款項淨額6.3%為其他主要臨牀階段候選藥物及主要臨牀前候選藥物撥資；所得款項淨額15.8%用於收購有潛力的技術及資產及擴張候選藥物管線，包括髮現新候選藥物及業務開發活動，及履行集團向翰思收購HX008項下的持續付款責任；及所得款項淨額9.4%用作一般公司用途。若超額配股權獲悉數行使，公司將就於超額配股權獲行使時發行的最多1903.1萬股H股收取額外所得款項淨額約1.303億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
